Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)
NDA FilingCRLOxylanthanum CarbonateNegative
AI Analysis
Summary
Unicycive Therapeutics received a Complete Response Letter from the FDA regarding its resubmitted oxylanthanum carbonate NDA for kidney disease treatment. The CRL indicates the application cannot be approved in its current form and requires additional information or modifications.
Outcome Details
Complete Response Letter received for resubmitted oxylanthanum carbonate NDA
Importance:8/10
Sentiment:
-0.80
FDANDAComplete Response Letterkidney diseasedrug development
Related Companies
Read the original article
Published by Drugs.com New Drug Applications on June 30, 2026 9:07 PM